CN109789115A - 用于治疗眼疾的方法 - Google Patents

用于治疗眼疾的方法 Download PDF

Info

Publication number
CN109789115A
CN109789115A CN201780056308.XA CN201780056308A CN109789115A CN 109789115 A CN109789115 A CN 109789115A CN 201780056308 A CN201780056308 A CN 201780056308A CN 109789115 A CN109789115 A CN 109789115A
Authority
CN
China
Prior art keywords
eye
compound
diabetes
alkyl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056308.XA
Other languages
English (en)
Chinese (zh)
Inventor
邱春亿
陈嘉南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhua Biotech Co ltd
Original Assignee
NatureWise Biotech and Medicals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatureWise Biotech and Medicals Corp filed Critical NatureWise Biotech and Medicals Corp
Publication of CN109789115A publication Critical patent/CN109789115A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780056308.XA 2016-09-29 2017-09-29 用于治疗眼疾的方法 Pending CN109789115A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401725P 2016-09-29 2016-09-29
US62/401,725 2016-09-29
PCT/CN2017/104345 WO2018059543A1 (en) 2016-09-29 2017-09-29 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
CN109789115A true CN109789115A (zh) 2019-05-21

Family

ID=61688114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056308.XA Pending CN109789115A (zh) 2016-09-29 2017-09-29 用于治疗眼疾的方法

Country Status (9)

Country Link
US (1) US11045435B2 (https=)
EP (1) EP3518913B1 (https=)
JP (3) JP2019531296A (https=)
KR (1) KR102341446B1 (https=)
CN (1) CN109789115A (https=)
CA (1) CA3038845C (https=)
MY (1) MY198731A (https=)
TW (1) TWI765917B (https=)
WO (1) WO2018059543A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
KR20240016352A (ko) * 2021-05-28 2024-02-06 노벨와이즈 파마슈티칼 코포레이션 약물-내성 암을 치료하기 위한 조성물 및 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100025640A1 (en) * 2007-05-02 2010-02-04 Andrij Pich Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
EP2236503A1 (en) * 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
CN101857554A (zh) * 2009-04-03 2010-10-13 彦臣生技药品股份有限公司 抑制组蛋白去乙酰化酶的肉桂化合物和其衍生物
EP2277387A1 (en) * 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
CN102131782A (zh) * 2008-08-27 2011-07-20 利奥制药有限公司 作为vegf-2受体和蛋白酪氨酸激酶抑制剂的吡啶衍生物
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4873904B2 (ja) * 2005-08-22 2012-02-08 国立大学法人弘前大学 眼血管血流障害改善剤
EP2135620A4 (en) 2007-03-28 2010-12-29 Santen Pharmaceutical Co Ltd AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE
US20110014294A1 (en) 2008-03-03 2011-01-20 Pharmalight Inc. Stimulation of ocular retrobulbar blood flow using ocular irritants
CN104080467B (zh) * 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
US9956254B2 (en) * 2015-02-26 2018-05-01 Naturewise Biotech & Medicals Corporation Extract of taiwanese propolis for treating ocular diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100025640A1 (en) * 2007-05-02 2010-02-04 Andrij Pich Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
CN102131782A (zh) * 2008-08-27 2011-07-20 利奥制药有限公司 作为vegf-2受体和蛋白酪氨酸激酶抑制剂的吡啶衍生物
EP2236503A1 (en) * 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
CN101857554A (zh) * 2009-04-03 2010-10-13 彦臣生技药品股份有限公司 抑制组蛋白去乙酰化酶的肉桂化合物和其衍生物
EP2277387A1 (en) * 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG,JIN-HONG等: "Corneal Neovascularization: An Anti-VEGF Therapy Review", 《SURVEY OF OPHTHALMOLOGY》 *
CHEN,TJ等: "NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway", 《CELLULAR PHYSIOLOGY AND BIOCHEMISTRY》 *
YANG, HUNG-YU等: "Anti-Cancer Activity of an Osthole Derivative,NBM-T-BMX-OS01: Targeting Vascular Endothelial Growth Factor Receptor Signaling and Angiogenesis", 《PLOS ONE》 *
牛彤彤等: "VEGF与眼内血管新生", 《眼科新进展》 *
陈庆魁主编: "《眼病诊治》", 31 October 1998 *

Also Published As

Publication number Publication date
JP2019531296A (ja) 2019-10-31
KR20190045304A (ko) 2019-05-02
JP2021138710A (ja) 2021-09-16
CA3038845A1 (en) 2018-04-05
CA3038845C (en) 2022-04-19
US20180085329A1 (en) 2018-03-29
EP3518913A1 (en) 2019-08-07
TW201828933A (zh) 2018-08-16
EP3518913C0 (en) 2025-07-23
WO2018059543A1 (en) 2018-04-05
EP3518913A4 (en) 2020-05-27
US11045435B2 (en) 2021-06-29
MY198731A (en) 2023-09-20
KR102341446B1 (ko) 2021-12-21
TWI765917B (zh) 2022-06-01
JP2023116748A (ja) 2023-08-22
EP3518913B1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
Ko et al. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma
Guan et al. Puerarin ameliorates retinal ganglion cell damage induced by retinal ischemia/reperfusion through inhibiting the activation of TLR4/NLRP3 inflammasome
TWI558405B (zh) Cicada active material, a preparation method thereof, a pharmaceutical composition comprising the same and a use thereof
Nuzzi et al. Glaucoma: biological trabecular and neuroretinal pathology with perspectives of therapy innovation and preventive diagnosis
RU2706704C2 (ru) Внутриглазная доставка биологически активных молекул с использованием ионтофореза
Zeng et al. Protective effect of the natural flavonoid naringenin in mouse models of retinal injury
Yu et al. NADPH and NAC synergistically inhibits chronic ocular hypertension-induced neurodegeneration and neuroinflammation through regulating p38/MAPK pathway and peroxidation
You et al. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis
CN109152776A (zh) 用于对视网膜神经退行性疾病的局部眼治疗的二肽基肽酶-4抑制剂
Lin et al. Retinal protection by fungal product theissenolactone B in a sodium iodate-induced AMD model through targeting retinal pigment epithelial matrix metalloproteinase-9 and microglia activity
JP2023116748A (ja) 眼疾患の処置方法
Huang et al. AZD6738 decreases intraocular pressure and inhibits fibrotic response in trabecular meshwork through CHK1/P53 pathway
CN106309492A (zh) 一种干细胞制剂及其制备方法和应用
CN101744795B (zh) 一种治疗鲜红斑痣的药物组合物及其制备方法
CN116650461A (zh) 咖啡酸苯乙酯滴及其眼液在制备治疗糖尿病视网膜病变药物中的应用
EP3682867B1 (en) Lutein-containing ophthalmic composition
CN108938687A (zh) 蒺藜在制备预防和治疗视网膜损伤性疾病药物中的应用
Navarro-Partida et al. Safety and tolerability of topical ophthalmic triamcinolone acetonide-loaded liposomes formulation and evaluation of its biologic activity in patients with diabetic macular edema. Pharmaceutics 2021; 13: 1–17
CN106389470A (zh) 一种干细胞制剂及其制备方法和应用
JP6266666B2 (ja) 医薬組成物および血管新生に関係する眼疾患の治療方法
RU2828991C1 (ru) Способ выбора оптимальной дозы, при которой препарат проявляет максимальную антиоксидантную активность, для введения в конъюнктивальную полость при заболеваниях глаза
ZARĘBSKA et al. Histological changes in the retina in experimental alloxan-induced diabetes in rabbits
CN119139229A (zh) 一种用于治疗眼外伤并发症的局部给药型药物及其制备方法
CN121714536A (zh) 一种靶向视网膜载药细胞外囊泡及其制备方法与应用
CN120884562A (zh) 载药聚合物、stat3抑制剂复合纳米颗粒及制备方法和在眼科药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002019

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20231227

Address after: Taipei City, Taiwan, China

Applicant after: Yuhua Biotech Co.,Ltd.

Address before: Taipei City, Taiwan, China

Applicant before: Naturewise Biotech & Medicals Corp.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20190521

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40002019

Country of ref document: HK